Remember CytRx got sued for not guessing correctly what FDA halt might do for the early topline. They will not risk another lawsuit by saying that money might be pouring in soon. It is better legal strategy have a negative bias on your estimates. It is also better strategy considering SP - the old and familiar underpromise and overdeliver.
BTW: It will take some years, say 2 to 4, before aldoxorubicin, if approved, will generate hefty royalty income. Replacing single use doxorubicin is not enough, not even in STS. Probably neither is replacement of dox plus IFOS combo with aldox plus IFOS. Aldox needs to replace dox in combinations with new SOC drugs like olaratumab (in STS) and that to happen will likely take a small trial ( < 100 subjects) per combo. Just to confirm that there is no nasty surprises after the switch. It follows that wider use of aldox will emerge some years after the first approval.
News 
Market Data 
Discover 
